Explore the evolving role of Adeno-Associated Virus (AAV) vectors in gene therapy and the immunological challenges that can impact clinical success.

This article examines the growing use of AAV vectors in gene replacement therapies, the impact of pre-existing immune responses, and the critical role of ELISpot assays in detecting low-frequency T-cell responses during clinical development.

Key topics include:

• The expanding application of AAV vectors in gene replacement therapies
• The challenge of pre-existing immunity and its implications for patient selection
• How ELISpot assays support the detection of low-frequency T-cell responses in clinical trials
• Strategies to optimize AAV-based therapies and improve patient safety and outcomes

As gene therapies continue to advance, understanding and monitoring immune responses is essential. Discover how ELISpot assays are helping drive more informed patient screening and supporting the development of safer, more effective gene therapies.